Ascendis Pharma A/S (NASDAQ:ASND) Trading Down 4.6% – Time to Sell?

Ascendis Pharma A/S (NASDAQ:ASND)’s share price dropped 4.6% during trading on Wednesday . The stock traded as low as $128.41 and last traded at $125.07. Approximately 13,803 shares were traded during trading, a decline of 97% from the average daily volume of 420,233 shares. The stock had previously closed at $131.06.

Analyst Ratings Changes

ASND has been the subject of a number of research analyst reports. Cantor Fitzgerald restated an “overweight” rating and issued a $170.00 price target on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. StockNews.com upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Wedbush reissued an “outperform” rating and issued a $181.00 price objective on shares of Ascendis Pharma A/S in a report on Friday, November 15th. UBS Group started coverage on shares of Ascendis Pharma A/S in a report on Tuesday, January 7th. They set a “buy” rating and a $196.00 target price on the stock. Finally, Oppenheimer lowered their price objective on shares of Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating for the company in a research report on Friday, November 15th. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $192.07.

Ascendis Pharma A/S Price Performance

The firm has a market capitalization of $7.72 billion, a P/E ratio of -15.74 and a beta of 0.65. The firm’s fifty day moving average price is $133.19 and its 200-day moving average price is $133.40.

Institutional Investors Weigh In On Ascendis Pharma A/S

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Wilmington Savings Fund Society FSB acquired a new stake in shares of Ascendis Pharma A/S during the third quarter valued at approximately $30,000. Groupama Asset Managment acquired a new stake in Ascendis Pharma A/S during the 3rd quarter valued at $60,000. Blue Trust Inc. lifted its holdings in shares of Ascendis Pharma A/S by 540.5% in the fourth quarter. Blue Trust Inc. now owns 506 shares of the biotechnology company’s stock valued at $76,000 after purchasing an additional 427 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Ascendis Pharma A/S by 58.0% in the fourth quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock worth $80,000 after buying an additional 214 shares during the period. Finally, Signaturefd LLC grew its holdings in shares of Ascendis Pharma A/S by 13.2% during the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 80 shares in the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.